Skilling the next pharma workforce: From compliance training to capability creation

Authored by: Puneet Rajput

The global pharmaceutical industry stands at a defining moment. What was once a sector rooted in process discipline and regulatory compliance is now transforming into a knowledge-intensive, innovation-driven ecosystem. From AI-enabled drug discovery to precision manufacturing and digital quality systems, the sector’s evolution demands a workforce that is not just compliant but capable, agile and globally competent.

For decades, compliance-led learning has anchored pharma training programmes. Employees have been trained to follow procedures, meet audit requirements, and adhere to Good Manufacturing Practices (GMP). While this approach has safeguarded quality and regulatory integrity, it has also created a narrow view of learning, one centred around obligation rather than opportunity. The sector’s new realities, such as AI-enabled discovery, digitised supply chains, and decentralised global operations, demand a strategic approach to upskilling.

From Training to Capability Creation

Modern pharma learning frameworks must evolve from linear, classroom-based training to dynamic, experiential learning ecosystems. The 70:20:10 principle, where 70% of learning comes from on-the-job experiences, 20% from peer interactions, and 10% from formal training, offers a pragmatic model. By embedding this structure, organisations can ensure that skilling is not episodic but continuous, contextual, and relevant.

For instance, a manufacturing associate could complement regulatory training with exposure to digital process validation tools (the 70%), learn from mentors or cross-functional collaborations (the 20%), and reinforce knowledge through structured learning modules (the 10%). This blended approach turns compliance into capability and learning into performance.

According to a 2025 industry study by Randstad Enterprise, 83% of life-sciences leaders say they struggle to find the right skills and 75% expect the shortage to worsen. The modern pharmaceutical workforce must be multidimensional, combining scientific expertise with digital fluency and regulatory agility. A process chemist today must interpret data analytics, a quality manager must manage AI-driven batch documentation, and a regulatory specialist must navigate frameworks across the U.S., EU, and emerging markets. This convergence of disciplines demands a deliberate approach to workforce design, one that positions continuous learning as a strategic business priority rather than a support function.

Moreover, leadership in the pharma sector must evolve from directing teams to developing them. Leaders who mentor, coach, and create learning opportunities multiply organisational capability. Skilling should therefore be embedded into managerial KPIs, ensuring that talent development is seen as a measure of business success.

A Global Skilling Imperative

Across the world, pharmaceutical powerhouses are rethinking workforce strategies to stay competitive in a digitally driven era. The U.S. and the European Union have launched joint initiatives to strengthen talent pipelines in biomanufacturing and advanced therapies, while regions like Singapore, Ireland, and South Korea are investing heavily in life sciences academies to bridge critical skill gaps. According to Deloitte’s 2024 Global Life Sciences Workforce Survey, nearly 72% of biopharma executives report that digital and analytics talent shortages are directly slowing innovation and compliance outcomes. 

As pharmaceutical supply chains globalise and operations become interdependent, skilling has evolved into a shared global priority rather than a national agenda. The goal is not just to build job-ready professionals but to create a globally fluent workforce capable of navigating diverse regulatory frameworks, leveraging digital technologies, and driving innovation across borders. This convergence marks the next frontier of competitiveness for the global pharma industry.

Aligning with National Momentum

India, home to the world’s third-largest pharmaceutical manufacturing base, is advancing its national skilling agenda through initiatives such as Skill India and the National Life Sciences Skill Development Council, creating a strong foundation for transformation. The objective extends beyond producing job-ready talent; it is about cultivating industry-ready professionals equipped to innovate, adapt, and lead in a complex global environment.

In a sector where precision, ethics, and innovation intersect, the true differentiator will be people who can seamlessly connect science and technology with purpose. Preparing them for that future is not a choice; it is a necessity. Around the world, leading pharma nations recognise a shared truth: the next frontier of progress will be defined as much by human capital as by scientific breakthroughs. The ability to unite science with digital intelligence and compliance with creativity will ultimately distinguish the leaders from the rest.